Losartan Potassium and Hydrochlorothiazide Tablets
Each film coated tablet contains:
Losartan Potassium 50 mg and Hydrochlorothiazide IP 12.5 mg
LORA-HC is a fixed-dose combination containing Losartan, an angiotensin II receptor (type AT1) antagonist, andhydrochlorothiazide, a thiazide diuretic. This combination provides synergistic blood pressure reduction in hypertension patients.
LORA-HC is indicated for the treatment of hypertension. This fixed-dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients.
Hypertensive patients with left ventricular hypertrophy
LORA-HC is indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy.
Dosage and administration:
The usual initial dosage is one tablet of LORA-HC daily. It may be increased, if necessary, to two tablets of LORA-HC once daily. The dosage however should be individualized.
Use in Patients with Renal Impairment
The usual regimens of therapy with LORA-HC may be followed as long as the patient’s creatinine clearance is >30 ml/min. LORA-HC is not recommended in patients with more severe renal impairment.
Hypertensive Patients with Left Ventricular Hypertrophy
Treatment should be initiated with losartan 50 mg once daily. If the blood pressure reduction is inadequate, LORA-HC should be substituted. If additional blood pressure reduction is needed, the dose may be increased to two tablets of LORA-HC daily
Hypersensitivity to either component
Hypersensitivity to other sulfonamide-derived drugs
Alu-Alu Blister of 10 Tablets.